LONDON (SHARECAST) - Irish drug giant Elan said the risk of a fatal brain disease in patients treated with its multiple sclerosis drug Tysabri “cannot be precisely estimated.” The group made the comments as it saw losses narrow for the half year on strong sales of the MS drug.
